SG11201807025SA - Crispr/cas systems for c-1 fixing bacteria - Google Patents

Crispr/cas systems for c-1 fixing bacteria

Info

Publication number
SG11201807025SA
SG11201807025SA SG11201807025SA SG11201807025SA SG11201807025SA SG 11201807025S A SG11201807025S A SG 11201807025SA SG 11201807025S A SG11201807025S A SG 11201807025SA SG 11201807025S A SG11201807025S A SG 11201807025SA SG 11201807025S A SG11201807025S A SG 11201807025SA
Authority
SG
Singapore
Prior art keywords
international
crispr
cas
lamon
skokie
Prior art date
Application number
SG11201807025SA
Inventor
Shilpa Nagaraju
Michael Koepke
Original Assignee
Lanzatech New Zealand Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lanzatech New Zealand Ltd filed Critical Lanzatech New Zealand Ltd
Publication of SG11201807025SA publication Critical patent/SG11201807025SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00—Technologies for the production of fuel of non-fossil origin
    • Y02E50/10—Biofuels, e.g. bio-diesel

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 111111110111101110101011111010111110111010111011111101110111101111101111011111 International Bureau .. .... ..Yejd (10) International Publication Number (43) International Publication Date ..... ...r .....1 WO 2017/147555 Al 31 August 2017 (31.08.2017) WIPO I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12N 15/74 (2006.01) C12N 15/11 (2006.01) kind C12N 9/16 (2006.01) AO, BZ, of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2017/019552 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (22) International Filing Date: KP, 25 February 2017 (25.02.2017) MD, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (25) Filing Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (26) Publication Language: English TH, ZA, ZM, ZW. TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (30) Priority Data: 62/300,532 26 February 2016 (26.02.2016) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: LANZATECH NEW ZEALAND LIMITED GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, [NZ/NZ]; c/o TMF Group, Level 12, 55 Shortland Street, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 1010 Auckland (NZ). TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (72) Inventors; and DK, LV, (71) Applicants (for US only): NAGARAJU, Shilpa [IN/US]; EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, _ 8045 Lamon Avenue, Suite 400, Skokie, IL 600077 (US). SM, KOEPKE, Michael [DE/US]; 8045 Lamon Avenue, Suite GW, KM, ML, MR, NE, SN, TD, TG). TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, 400, Skokie, IL 60077 (US). Published: Agent: SCHOEN, Andrea, E.; 8045 Lamon Avenue, — with (74) international search report (Art. 21(3)) Suite 400, Skokie, IL 60077 (US). = = = = = = = = = = = = Title: CRISPR/CAS SYSTEMS FOR C-1 FIXING BACTERIA (54) 1-1 ,, ,,, .nom ,..: „ 11 in 11 in 11 in IN gRNWI 1 r a „ . i 71- 1-1 Fig. IC - ---I 1-1 (57) : The invention provides methods of genetically engineering a Cl-fixing bacterium using a Clustered Regularly Inter - 0 spaced Short Palindromic Repeats (CRISPR)/CRISPR-associated (Cas) (CRISPR/Cas) system. Preferably, the Cas protein is under \" the control of an inducible promoter.
SG11201807025SA 2016-02-26 2017-02-25 Crispr/cas systems for c-1 fixing bacteria SG11201807025SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662300532P 2016-02-26 2016-02-26
PCT/US2017/019552 WO2017147555A1 (en) 2016-02-26 2017-02-25 Crispr/cas systems for c-1 fixing bacteria

Publications (1)

Publication Number Publication Date
SG11201807025SA true SG11201807025SA (en) 2018-09-27

Family

ID=59679442

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201807025SA SG11201807025SA (en) 2016-02-26 2017-02-25 Crispr/cas systems for c-1 fixing bacteria

Country Status (9)

Country Link
US (1) US11441149B2 (en)
EP (1) EP3420089B1 (en)
KR (1) KR20180110144A (en)
CN (2) CN114908093A (en)
AU (1) AU2017222688B2 (en)
CA (1) CA3015665C (en)
DK (1) DK3420089T3 (en)
SG (1) SG11201807025SA (en)
WO (1) WO2017147555A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9840699B2 (en) 2013-12-12 2017-12-12 President And Fellows Of Harvard College Methods for nucleic acid editing
EP3177718B1 (en) 2014-07-30 2022-03-16 President and Fellows of Harvard College Cas9 proteins including ligand-dependent inteins
EP3365356B1 (en) 2015-10-23 2023-06-28 President and Fellows of Harvard College Nucleobase editors and uses thereof
GB2568182A (en) 2016-08-03 2019-05-08 Harvard College Adenosine nucleobase editors and uses thereof
AU2017308889B2 (en) 2016-08-09 2023-11-09 President And Fellows Of Harvard College Programmable Cas9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
KR102622411B1 (en) 2016-10-14 2024-01-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 AAV delivery of nucleobase editor
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
WO2018165629A1 (en) 2017-03-10 2018-09-13 President And Fellows Of Harvard College Cytosine to guanine base editor
EP3604519A4 (en) * 2017-03-22 2021-01-06 National University Corporation Kobe University Method for converting nucleic acid sequence of cell specifically converting nucleic acid base of targeted dna using cell endogenous dna modifying enzyme, and molecular complex used therein
EP3601562A1 (en) 2017-03-23 2020-02-05 President and Fellows of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
EP3676376A2 (en) 2017-08-30 2020-07-08 President and Fellows of Harvard College High efficiency base editors comprising gam
CA3078718A1 (en) * 2017-10-13 2019-04-18 Intrexon Corporation Advanced genome editing
KR20200121782A (en) 2017-10-16 2020-10-26 더 브로드 인스티튜트, 인코퍼레이티드 Uses of adenosine base editor
CN107937501A (en) * 2017-11-24 2018-04-20 安徽师范大学 A kind of method of fast and convenient screening CRISPR/Cas gene editing positive objects
US11571441B2 (en) * 2018-03-26 2023-02-07 Whitehead Institute For Biomedical Research Sideroflexins as mitochondrial serine transporters
WO2020176389A1 (en) * 2019-02-25 2020-09-03 Caribou Biosciences, Inc. Plasmids for gene editing
BR112021018606A2 (en) 2019-03-19 2021-11-23 Harvard College Methods and compositions for editing nucleotide sequences
DE112021002672T5 (en) 2020-05-08 2023-04-13 President And Fellows Of Harvard College METHODS AND COMPOSITIONS FOR EDIT BOTH STRANDS SIMULTANEOUSLY OF A DOUBLE STRANDED NUCLEOTIDE TARGET SEQUENCE
WO2023111304A1 (en) 2021-12-16 2023-06-22 Danmarks Tekniske Universitet Temperature-inducible expression system for thermophilic organisms

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593886A (en) 1992-10-30 1997-01-14 Gaddy; James L. Clostridium stain which produces acetic acid from waste gases
UA72220C2 (en) 1998-09-08 2005-02-15 Байоенджініерінг Рісорсиз, Інк. Water-immiscible mixture solvent/cosolvent for extracting acetic acid, a method for producing acetic acid (variants), a method for anaerobic microbial fermentation for obtaining acetic acid (variants), modified solvent and a method for obtaining thereof
NZ546496A (en) 2006-04-07 2008-09-26 Lanzatech New Zealand Ltd Gas treatment process
US7704723B2 (en) 2006-08-31 2010-04-27 The Board Of Regents For Oklahoma State University Isolation and characterization of novel clostridial species
NZ553984A (en) 2007-03-19 2009-07-31 Lanzatech New Zealand Ltd Alcohol production process
KR101375029B1 (en) 2007-11-13 2014-03-14 란자테크 뉴질랜드 리미티드 Novel bacteria and methods of use thereof
EP2307556B1 (en) 2008-06-09 2020-08-05 Lanzatech New Zealand Limited Production of butanediol by anaerobic microbial fermentation
US8591412B2 (en) * 2009-11-18 2013-11-26 Nohands, Llc Method and system for preventing virus-related obesity and obesity related diseases
WO2011112103A1 (en) 2010-03-10 2011-09-15 Lanzatech New Zealand Limited Acid production by fermentation
CN103415618A (en) 2010-08-19 2013-11-27 新西兰郎泽科技公司 A process for producing chemicals by using microbial fermentation of substrates comprising carbon monoxide
CN103282505A (en) 2010-08-26 2013-09-04 新西兰郎泽科技公司 Process for producing ethanol and ethylene via fermentation
US20110236941A1 (en) 2010-10-22 2011-09-29 Lanzatech New Zealand Limited Recombinant microorganism and methods of production thereof
TWI541348B (en) 2011-02-25 2016-07-11 藍瑟科技紐西蘭有限公司 Recombinant carboxydotrophic acetogenic microorganisms and uses therefor
WO2013036147A2 (en) 2011-09-08 2013-03-14 Lanzatech New Zealand Limited A fermentation process
ES2960803T3 (en) * 2012-05-25 2024-03-06 Univ California Methods and compositions for RNA-directed modification of target DNA and for modulation of RNA-directed transcription
IN2014DN10168A (en) 2012-05-30 2015-08-21 Lanzatech New Zealand Ltd
US20130323820A1 (en) 2012-06-01 2013-12-05 Lanzatech New Zealand Limited Recombinant microorganisms and uses therefor
CN104919037A (en) * 2012-06-08 2015-09-16 朗泽科技新西兰有限公司 Recombinant microorganisms and uses therefor
CN104540382A (en) * 2012-06-12 2015-04-22 弗·哈夫曼-拉罗切有限公司 Methods and compositions for generating conditional knock-out alleles
US9347076B2 (en) 2012-06-21 2016-05-24 Lanzatech New Zealand Limited Recombinant microorganisms that make biodiesel
IL239344B1 (en) * 2012-12-12 2024-02-01 Broad Inst Inc Engineering of systems, methods and optimized guide compositions for sequence manipulation
SG10201912328UA (en) * 2012-12-12 2020-02-27 Broad Inst Inc Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
CN103865938B (en) * 2012-12-16 2016-10-05 山东国际生物科技园发展有限公司 The application of clostridium difficile exotoxin A carboxy-terminal stream cipher optimization gene fragment, expression vector establishment method and expressing protein thereof
US8787096B1 (en) 2013-01-16 2014-07-22 Qualcomm Incorporated N-well switching circuit
AU2014281028B2 (en) * 2013-06-17 2020-09-10 Massachusetts Institute Of Technology Delivery and use of the CRISPR-Cas systems, vectors and compositions for hepatic targeting and therapy
SG10201801658XA (en) * 2013-08-29 2018-03-28 Univ Temple Methods and compositions for rna-guided treatment of hiv infection
US9388430B2 (en) * 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
WO2015054507A1 (en) * 2013-10-10 2015-04-16 Pronutria, Inc. Nutritive polypeptide production systems, and methods of manufacture and use thereof
EP3835419A1 (en) * 2013-12-12 2021-06-16 The Regents of The University of California Methods and compositions for modifying a single stranded target nucleic acid
US11439712B2 (en) * 2014-04-08 2022-09-13 North Carolina State University Methods and compositions for RNA-directed repression of transcription using CRISPR-associated genes
GB201406970D0 (en) * 2014-04-17 2014-06-04 Green Biologics Ltd Targeted mutations
WO2016054225A1 (en) * 2014-09-30 2016-04-07 Stc.Unm Plasmid delivery in the treatment of cancer and other disease states
CN104404036B (en) * 2014-11-03 2017-12-01 赛业（苏州）生物科技有限公司 Conditional gene knockout method based on CRISPR/Cas9 technologies
AU2015363113B2 (en) * 2014-12-17 2021-03-11 E. I. Du Pont De Nemours And Company Compositions and methods for efficient gene editing in E. coli using guide RNA/Cas endonuclease systems in combination with circular polynucleotide modification templates

Also Published As

Publication number Publication date
DK3420089T3 (en) 2022-03-14
CA3015665A1 (en) 2017-08-31
CN114908093A (en) 2022-08-16
EP3420089A4 (en) 2019-08-14
EP3420089B1 (en) 2021-12-29
AU2017222688B2 (en) 2023-05-25
WO2017147555A1 (en) 2017-08-31
US11441149B2 (en) 2022-09-13
CA3015665C (en) 2020-09-22
AU2017222688A1 (en) 2018-09-13
CN109072245B (en) 2022-06-14
KR20180110144A (en) 2018-10-08
CN109072245A (en) 2018-12-21
US20170247710A1 (en) 2017-08-31
EP3420089A1 (en) 2019-01-02

Similar Documents

Publication Publication Date Title
SG11201807025SA (en) Crispr/cas systems for c-1 fixing bacteria
SG11201906395PA (en) Blockchain based data processing method and device
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201808990QA (en) Compositions for topical application of compounds
SG11201804807VA (en) Computer architecture and method for modifying data intake parameters based on a predictive model
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201804372PA (en) Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9
SG11201910101SA (en) Alphavirus neoantigen vectors
SG11201809041TA (en) Compositions and methods for selective protein expression
SG11201807307VA (en) System and method for aerial system discrimination and action
SG11201907618RA (en) Automated storage and retrieval systems and methods
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201808076UA (en) Facilitating vehicle driving and self-driving
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201807279QA (en) Binding proteins and methods of use thereof
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201808149WA (en) Container handling equipment controller arrangement
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201407483YA (en) Compositions and methods for modulating smn gene family expression
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201806284TA (en) Low pressure separator having an internal divider and uses therefor
SG11201901517YA (en) Wireless telecommunications methods and apparatus using system information value tag
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201810471YA (en) T cell expansion